<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The present study was performed to investigate the clinical implications of an implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) in patients with vasospastic <z:mp ids='MP_0006112'>angina</z:mp> (VSA) resuscitated from lethal <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: The prognosis of VSA is known to be good with medication; however, <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> and cardiopulmonary arrest are rare but life-threatening complications of this disease </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> is a proven modality for patients with <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, but the clinical implications in this population remain to be elucidated </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We conducted a retrospective, observational, multicenter study involving patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> due to documented <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> and VSA diagnosed by <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> provocation test </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were followed up for appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy, sudden <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo>, or <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0000001'>all</z:hpo> causes </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Twenty-three patients were included in the present study and completely followed up </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients are still alive </plain></SENT>
<SENT sid="7" pm="."><plain>During a follow-up of 2.9 years (median 2.1 years), 4 <z:hpo ids='HP_0001663'>ventricular fibrillations</z:hpo> and 1 episode of <z:e sem="disease" ids="C0340861" disease_type="Disease or Syndrome" abbrv="EMD">pulseless electrical activity</z:e> occurred in 5 patients (21.7%) </plain></SENT>
<SENT sid="8" pm="."><plain>There were no statistically significant differences in patient characteristics between the recurrence and nonrecurrence groups, including medication, smoking status, and whether the patient was or was not free of symptoms after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Patients with VSA and lethal <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> are a population at high risk for recurrence of cardiopulmonary arrest, and there is no reliable indicator for predicting recurrence of <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Insertion of an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> with medication for VSA is appropriate for this high-risk population </plain></SENT>
</text></document>